SCHEMBL6887783

SCHEMBL6887783

CCOC(=O)[C@H](Cc1ccc(Nc2nc3ccccc3n2C)cc1)Nc1c(OC(C)C)c(=O)c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.42
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
HDAC6 Q9UBN7 1/20 0.38
DRD2 P14416 1/20 0.37
TBXA2R P21731 1/20 0.37
P2RX3 P56373 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
PDE10A Q9Y233 2/20 0.36
PYGM P11217 2/20 0.35
ITGB1 P05556 1/20 0.35
ITGA4 P13612 1/20 0.35
TP53 P04637 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7105519 0.80 ELANE (0.42) ELANENPC1RAB9AHDAC6ITGB1
SCHEMBL7105524 0.80 ELANE (0.42) ELANENPC1RAB9AHDAC6ITGB1
SCHEMBL7260150 0.79 RAB9A (0.39) ELANENPC1RAB9ATP53KDM4E
SCHEMBL7260141 0.79 RAB9A (0.39) ELANENPC1RAB9ATP53KDM4E
SCHEMBL6884435 0.78 NPC1 (0.42) ELANENPC1RAB9AHDAC6DRD2
SCHEMBL6888867 0.77 NPC1 (0.43) ELANENPC1RAB9AHDAC6DRD2
SCHEMBL6888864 0.77 NPC1 (0.43) ELANENPC1RAB9AHDAC6DRD2
SCHEMBL7258656 0.74 ELANE (0.38) ELANENPC1PDE10AITGB1ITGA4
Trifluoroacetic Acid SCHEMBL6884189 0.73 NPC1 (0.46) NPC1RAB9AHDAC6DRD2TBXA2R
SCHEMBL7049316 0.73 NPC1 (0.39) ELANENPC1RAB9AHDAC6DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6740654-B2 INHIBIT THE BINDING OF INTEGRINS TO THEIR LIGANDS AND ARE OF USE IN THE PROPHYLAXIS AND TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS, OR DISORDERS INVOLVING THE INAPPROPRIATE GROWTH OR MIGRATION OF CELLS. CELLTECH R & D LIMITED (GB) 2004-05-25 US disclosed